Financial News · Live Terminal

Page 570 of 692

Cantor Fitzgerald Adjusts Regeneron Pharmaceuticals PT to $800 From $779

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $706.12, Change: $+19.76, Percent Change: +2.88%

$REGN

Wire146d ago

Wells Fargo Adjusts Regeneron Pharmaceuticals PT to $800 From $825

Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $880.77, according to analysts polled by FactSet.Price: $706.12, Change: $+19.76, Percent Change: +2.88%

$REGN

Wire146d ago

Piper Sandler Adjusts Price Target on Chipotle Mexican Grill to $42 From $44

Chipotle Mexican Grill (CMG) has an average rating of overweight and mean price target of $43.80, according to analysts polled by FactSet.Price: $34.21, Change: $+1.22, Percent Change: +3.70%

$CMG

Wire146d ago

Etsy Faces Sustainability Questions Despite Return to Growth, Morgan Stanley Says

Etsy (ETSY) has returned to mid-single-digit gross merchandise sales growth in the first half of 2026, but the durability of that momentum remains uncertain, Morgan Stanley said in a report Thursday.Q1 GMS rose 5.5% year over year, with the company guiding to 3% to 5% growth in the second quarter, marking a return to mid-single-digit expansion for the "first time since 2021," the report said.Cohort data showed signs of stabilization, with "habitual" and "repeat" buyers flattening sequentially after prior declines, lower churn, moderating customer acquisition costs and improved GMS per buyer, the investment bank said, adding that "marketing efficiency" has also improved.However, much of the recent growth may be driven by "temporary" factors, including pricing, favorable macro trends, foreign exchange and easier comparisons, and continues to model low-single-digit GMS growth over the medium term, Morgan Stanley said.Morgan Stanley raised its 2026 and 2027 GMS estimates by about 2% and earnings before interest, taxes, depreciation, and amortization forecasts by roughly 5%, citing improved "profitability" and expectations for continued net active buyer additions.It also increased its price target on Etsy to $64 from $60 while maintaining an equal-weight rating, citing a "balanced risk-reward" profile.Price: $64.09, Change: $-5.51, Percent Change: -7.92%

$ETSY

Wire146d ago

Stifel Adjusts Price Target on GE Healthcare Technologies to $80 From $98

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $59.99, Change: $+0.51, Percent Change: +0.85%

$GEHC

Wire146d ago

HSBC Adjusts Price Target on GE Healthcare Technologies to $90 From $100

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $59.99, Change: $+0.51, Percent Change: +0.85%

$GEHC

Wire146d ago

Evercore ISI Adjusts Price Target on GE Healthcare Technologies to $80 From $85

GE Healthcare Technologies (GEHC) has an average rating of overweight and mean price target of $80.06, according to analysts polled by FactSet.Price: $59.99, Change: $+0.51, Percent Change: +0.85%

$GEHC

Wire146d ago

Blue Owl Reports 10x Return on SpaceX Investment, Sells About Half at $1.25 Trillion Valuation

Blue Owl Capital (OWL) said Thursday on its earnings call that it made about 10x the money it invested in SpaceX and that it sold about half of it at a $1.25 trillion valuation.Shares of Blue Owl were up more than 11% in Thursday trading.Price: $9.89, Change: $+1.01, Percent Change: +11.37%

$OWL

Wire146d ago

Goldman Sachs Adjusts Price Target on Chipotle Mexican Grill to $44 From $43

Chipotle Mexican Grill (CMG) has an average rating of overweight and mean price target of $43.80, according to analysts polled by FactSet.Price: $34.24, Change: $+1.25, Percent Change: +3.77%

$CMG

Wire146d ago

Barclays Adjusts Price Target on Chipotle Mexican Grill to $38 From $40

Chipotle Mexican Grill (CMG) has an average rating of overweight and mean price target of $43.80, according to analysts polled by FactSet.Price: $34.24, Change: $+1.25, Percent Change: +3.77%

$CMG

Wire146d ago

Citigroup Adjusts Price Target on Chipotle Mexican Grill to $46 From $44

Chipotle Mexican Grill (CMG) has an average rating of overweight and mean price target of $43.80, according to analysts polled by FactSet.Price: $34.24, Change: $+1.25, Percent Change: +3.77%

$CMG

Wire146d ago

BNP Paribas Adjusts Price Target on Chipotle Mexican Grill to $39 From $37

Chipotle Mexican Grill (CMG) has an average rating of overweight and mean price target of $43.80, according to analysts polled by FactSet.Price: $34.24, Change: $+1.25, Percent Change: +3.77%

$CMG

Wire146d ago

Blue Owl Reports 10x Return on SpaceX Investment, Sells About Half at $1.25 Trillion Valuation

$OWL

Wire146d ago

Markel Group Pushed by Jana to Divest Ventures, Repurchase $2 billion of Stock, Bloomberg Reports

$MKL

Wire146d ago

AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says

AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are "overdone," BofA Securities said in a note Thursday.The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson & Johnson's (JNJ) IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers "one of the best" growth profiles in the industry, with room for upside on the success of its early and mid-pipeline efforts, the brokerage said.BofA upgraded AbbVie to buy from neutral, and raised the price target to $234 from $226.Shares of AbbVie were up more than 4% in Thursday trading.Price: $212.77, Change: $+8.88, Percent Change: +4.36%

$ABBV$JNJ

Wire146d ago

Wingstop's Plans Have Clarity, but Questions About Effectiveness Remain, Morgan Stanley Says

Wingstop's (WING) plans going forward have clarity, but questions remain about their effectiveness, Morgan Stanley analysts said in a Thursday note.Analysts said that while the company's domestic same store sales decline of 8.7% was understood, it was lower than expectations.Morgan Stanley said that Wingstop's Smart Kitchen system "is working but rather slowly and clearly not stemming customer pullback."Morgan Stanley said, however, that the stock is around a level where the risk/reward skew is still "compelling."Analysts retained an overweight rating on the stock, but lowered its price target to $255 from $265.Shares of the company were down 3.2% in Thursday's trading.Price: $165.59, Change: $-5.63, Percent Change: -3.29%

$WING

Wire146d ago

Chefs' Warehouse Q1 Seen as 'High-End Bright Spot' on Strong Growth, Morgan Stanley Says

Chefs' Warehouse (CHEF) delivered a strong Q1, with results beating expectations across key metrics and reinforcing momentum in its core business, as organic revenue growth reached 10.4%, ahead of consensus estimates of about 7%, Morgan Stanley said in a Thursday note.The analysts said the upside was driven by strong volume growth and favorable mix, with 4.1% inflation contributing, while adjusted earnings before interest, taxes, depreciation, and amortization of $60 million beat estimates, with margins expanding about 70 basis points to 5.7% on operating efficiency and top-line strength.Morgan Stanley said Middle East concerns were less severe than feared, with only a roughly 50 basis point headwind in the quarter; volumes are about 75% of last year's levels and could weigh by around 50 basis points per month if conditions persist.The researchers noted continued momentum into the current quarter, with double-digit organic growth carrying into April, indicating resilient demand despite a mixed macro backdrop.Morgan Stanley maintained an overweight rating on the stock and raised its price target to $83 from $76.Price: $76.14, Change: $+0.36, Percent Change: +0.48%

$CHEF

Wire146d ago

TD Cowen Adjusts Price Target on Generac to $285 From $255

Generac (GNRC) has an average rating of overweight and mean price target of $267.50, according to analysts polled by FactSet.Price: $256.70, Change: $+3.78, Percent Change: +1.49%

$GNRC

Wire146d ago

Meta Platforms' Increasing Investments Fuel Concerns Over Returns, BofA Says

Meta Platforms' (META) increasing investments are driving concerns over returns, but the company's artificial intelligence execution and upcoming product launches could lift optimism, BofA Securities said in a Thursday note.The company raised its 2026 capital expenditures guidance to between $125 billion and $145 billion, from $115 billion to $135 billion previously, as it reported Q1 earnings of $10.44 per diluted share and revenue of $56.31 billion, both increasing year over year, the firm noted.BofA Securities said Meta's AI investment cycle is bigger than expected, but the company's growing AI capacity could open new opportunities. In-house AI models could improve the social media giant's core business, the brokerage added.BofA Securities raised its price target on Meta Platforms to $835 from $820, while reiterating buy rating.Price: $606.74, Change: $-62.38, Percent Change: -9.32%

$META

Wire146d ago

JPMorgan Adjusts Price Target on Verisk Analytics to $230 From $220

Verisk Analytics (VRSK) has an average rating of overweight and mean price target of $227.29, according to analysts polled by FactSet.Price: $184.89, Change: $-3.31, Percent Change: -1.76%

$VRSK

Showing 11381-11400 of 13825